ImmunoGenesis to present IMGS-001 Phase 1a/1b Clinical Study Updates at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
IMGS-001 is first dual-specific PD-L1/PD-L2 antibody with cytotoxic killing function and is designed to treat the many "immune-excluded" cancers that are resistant to existing immunotherapies
HOUSTON , May 30, 2025 /CNW/ -- ImmunoGenesis, a clinical-stage biotech company developing innovative, science-driven immunotherapies, announced today that a Trial in Progress poster for its first-in-human, Phase 1a/ 1b clinical trial of IMGS-001 will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago, Illinois from May 30 to June 3, 2025 .
This Phase 1a/ 1b first-in-human, open-label, multicenter study (NCT06014502) includes a dose escalation and an expansion portion to evaluate the safety, pharmacokinetics, and preliminary anti-tumor activity of IMGS-001 in adult patients with locally advanced or metastatic solid tumors refractory to standard-of-care treatment. The study will enroll approximately 25 patients in Phase 1a and up to 250 in Phase 1b . The first three of five planned dose cohorts have completed without any dose limiting toxicities (DLTs), with cohort 4 (10 mg/kg) now enrolling.
"This clinical trial is an important first step to understand how IMGS-001 may potentially remove immunosuppressive cells while improving PD-1 pathway blockade to treat otherwise immunoresistant tumors that represent a significant unmet medical need," stated Charles Schweizer , PhD, Senior Vice President of Clinical Development at ImmunoGenesis. "We are pleased to discuss the study plan and progress at this important conference as we look ahead to sharing results."
"We are encouraged by the early performance of IMGS-001 as we proceed with Phase 1 dose escalation in patients with a variety of advanced solid tumors," said James Barlow , President and CEO of ImmunoGenesis. "Initial low doses administered to date have been well-tolerated with no dose-limiting toxicities, and we are seeing promising early signs of anti-tumor activity in patients who have failed prior treatments. IMGS-001 has the potential to be a foundational therapy for immune-excluded tumors, addressing a major unmet need."
ASCO Poster Presentation
Title: A Phase 1a/ 1b study to evaluate the safety, tolerability, Pharmakokinetics, and anti-tumor activity of IMGS-001 in Patients with relapsed or refractory advanced solid tumors.
Abstract: TS2686 | Poster Bd #: 324a
Track: Developmental Therapeutics—Immunotherapy
Location: Hall A -Posters and Exhibits | On Demand
Time: June 2, 2025 , 1:30 PM – 4:30 PM CDT
About ImmunoGenesis
ImmunoGenesis is a clinical-stage biotech company dedicated to transforming immuno-oncology by targeting key mechanisms of immune resistance. The company's lead product, IMGS-001, is a cytotoxic, dual-specific PD-L1/PD-L2 antibody currently in a Phase 1a/b clinical trial for the treatment of immune-excluded ("cold") tumors, which account for more than half of all cancers. In addition to its lead program, the company is developing a number of novel approaches to overcome immune resistance in cold tumors. ImmunoGenesis designs therapies to address the pathology of these tumors, overcoming immune exclusion to elicit a robust immune response. For more information, visit www.immunogenesis.com.
About IMGS-001, a PD-L1/PD-L2 Dual-Specific Inhibitor
IMGS-001, the lead program at ImmunoGenesis, is a PD-L1/PD-L2 dual-specific monoclonal antibody with engineered cytotoxic effector function. IMGS-001 is the first molecule in clinical testing to target PD-L2 in addition to PD-L1, potentially improving blockade of the PD-1 pathway. The engineered effector function may enable IMGS-001 to eliminate immunosuppressive PD-L1- and/or PD-L2-expressing cells present in the tumor microenvironment, providing the potential to overcome immune resistance in immune-excluded tumors. Preclinical data showed that IMGS-001 drove higher response rates in head-to-head studies compared to currently available immunotherapies. IMGS-001 may provide a new foundational therapy with its innovative multitasking mechanism of superior blockade and cytotoxic effector function. IMGS-001 is being developed with support from the Cancer Prevention and Research Institute of Texas (CPRIT) DP200094 as well as an investment from the Cancer Focus Fund, LP.
Contact
ImmunoGenesis
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
Septic System Owners Are Ditching the Old Way of Cleaning Toilets
You're already cleaning your toilet — why not clean your septic system too, with the same flush? The first and only 2-in-1 cleaner that cleans your toilet and treats your septic system at the same time. Instead of using harsh chemicals that can harm septic health, this foaming formula uses Dr. Pooper's proven Accelerator by Dr. Pooper® bio-technology to safely break down septic solids. Hockley, TX - Jun 3, 2025 - In a market filled with 'single-purpose' bathroom cleaners, the new Accelerator by Dr. Pooper® Toilet Bowl & Septic Cleaner is simplifying routines — and septic system maintenance — with a smarter, dual-function approach. What makes this product so different? It's the first and only 2-in-1 cleaner that cleans your toilet and treats your septic system at the same time. Instead of using harsh chemicals that can harm septic health, this foaming formula uses Dr. Pooper's proven Accelerator by Dr. Pooper® bio-technology to safely break down solids in your pipes, tank, and drain field. 'It's the easiest and most effective septic maintenance you'll ever do,' said Chris Denny, CEO and co-founder of Dr. Pooper. 'You're already cleaning your toilet — why not clean your septic system too, with the same flush?' The 2-in-1 Toilet Bowl & Septic Cleaner has quickly become a favorite among homeowners with septic systems, especially those looking to: And because it's totally non-toxic, there's no risk to pets, kids, or groundwater. The 2-in-1 Toilet Bowl & Septic Cleaner is available now on Media Contact Company Name: Dr. Pooper Enterprise LLC Contact Person: Chris Denny Email: Send Email Phone: 8323016075 Address: 27122 FM 2920 City: Hockley State: Texas Country: United States Website:
Globe and Mail
an hour ago
- Globe and Mail
FTI Consulting: A Hidden Gem or Just Fine?
Explore the exciting world of FTI Consulting (NYSE: FCN) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities! *Stock prices used were the prices of April 28, 2025. The video was published on Jun. 3, 2025. Should you invest $1,000 in FTI Consulting right now? Before you buy stock in FTI Consulting, consider this: Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and FTI Consulting wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $657,385!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $842,015!* Now, it's worth noting Stock Advisor 's total average return is987% — a market-crushing outperformance compared to171%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 2, 2025
Globe and Mail
an hour ago
- Globe and Mail
Trump administration scraps guidance on emergency abortions
The Trump administration announced on Tuesday that it would revoke guidance to the nation's hospitals that directed them to provide emergency abortions for women when they are necessary to stabilize their medical condition. That guidance was issued to hospitals in 2022, weeks after the U.S. Supreme Court upended national abortion rights in the U.S. It was an effort by the Biden administration to preserve abortion access for extreme cases in which women were experiencing medical emergencies and needed an abortion to prevent organ loss or severe hemorrhaging, among other serious complications. The Biden administration had argued that hospitals – including states with near-total bans – needed to provide emergency abortions under the Emergency Medical Treatment and Active Labor Act. That law requires emergency rooms that receive Medicare dollars to provide an exam and stabilizing treatment for all patients. Nearly all emergency rooms in the U.S. rely on Medicare funds. More people in U.S. are obtaining abortions, but fewer are traveling to other states for it, survey finds The Trump administration announced on Tuesday that it would no longer enforce that policy. The move prompted concerns from some doctors and abortion rights advocates that women will not get emergency abortions in states with strict bans. 'The Trump Administration would rather women die in emergency rooms than receive life-saving abortions,' Nancy Northup, president and CEO of the Center for Reproductive Rights, said in a statement. 'In pulling back guidance, this administration is feeding the fear and confusion that already exists at hospitals in every state where abortion is banned. Hospitals need more guidance, not less, to stop them from turning away patients experiencing pregnancy crises.' Anti-abortion advocates praised the move, however. Marjorie Dannenfelser, president of SBA Pro-Life America, said in a statement that the Biden-era policy had been a way to expand abortion access in states where it was banned. 'Democrats have created confusion on this fact to justify their extremely unpopular agenda for all-trimester abortion,' she said. 'In situations where every minute counts, their lies lead to delayed care and put women in needless, unacceptable danger.' An Associated Press investigation last year found that, even with the Biden administration's guidance, dozens of pregnant women were being turned away from emergency rooms, including some who needed emergency abortions. The Centers for Medicare and Medicaid Services, which investigates hospitals that are not in compliance, said in a statement that it will continue to enforce the federal law that, 'including for identified emergency medical conditions that place the health of a pregnant woman or her unborn child in serious jeopardy.' But CMS added that it would also 'rectify any perceived legal confusion and instability created by the former administration's actions.' The Biden administration sued Idaho over its abortion law that initially only allowed abortions to save the life of the mother. The federal government had argued before the U.S. Supreme Court last year that Idaho's law was in conflict with the federal law, which requires stabilizing treatment that prevents a patient's condition from worsening. The U.S. Supreme Court issued a procedural ruling in the case last year that left key questions unanswered about whether doctors in abortion ban states can terminate pregnancies when a woman is at risk of serious infection, organ loss or hemorrhage.
